CQP(000950)2024-10-24 08:05Financial Performance - The company's operating revenue for Q3 2024 reached ¥19,913,430,252.60, representing a 12.70% increase compared to the same period last year[3] - Net profit attributable to shareholders was ¥54,137,049.22, a significant increase of 1,269.44% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥58,792,227.20, showing a growth of 1,342.83% compared to the previous year[3] - Total operating revenue for Q3 2024 reached CNY 59.69 billion, an increase from CNY 58.38 billion in Q3 2023, representing a growth of approximately 2.24%[17] - The company's net profit attributable to shareholders increased to CNY 7.15 billion in Q3 2024 from CNY 6.95 billion in Q3 2023, reflecting a growth of approximately 3.87%[17] - The company reported a total profit of CNY 547,081,361.52, down 31.2% from CNY 794,733,136.46 in the previous year[18] - Basic earnings per share for Q3 2024 were CNY 0.17, a decrease from CNY 0.30 in Q3 2023[19] - The total comprehensive income for the period was CNY 406,574,609.94, compared to CNY 623,809,861.59 in the prior year, indicating a decline of 34.9%[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥66,604,307,198.21, reflecting a 4.85% increase from the end of the previous year[3] - Total assets as of Q3 2024 amounted to CNY 66.60 billion, compared to CNY 63.52 billion in Q3 2023, marking an increase of about 4.36%[17] - Total liabilities reached CNY 51.02 billion in Q3 2024, up from CNY 48.02 billion in Q3 2023, which is an increase of approximately 6.23%[17] - Non-current liabilities totaled CNY 6.35 billion in Q3 2024, compared to CNY 5.16 billion in Q3 2023, indicating a growth of around 23.19%[17] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥3,150,267,721.05, which is a 6.18% increase in outflow compared to the previous year[8] - The net cash flow from operating activities was -3,150,267,721.05 CNY, compared to -2,966,798,367.22 CNY in the previous year, indicating a decline[21] - Total cash outflow from operating activities reached 69,193,727,855.29 CNY, up from 64,441,722,382.91 CNY year-over-year[21] - Cash inflow from financing activities totaled 19,960,387,270.76 CNY, down from 21,112,911,978.75 CNY in the previous year[21] - The net cash flow from financing activities was 18,901,318,624.93 CNY, compared to 19,060,273,057.43 CNY in the previous year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,376, with the top 10 shareholders holding a combined 38.47% of shares[9] - Chongqing Medical Health Industry Co., Ltd. holds 664,900,806 shares, accounting for 38.47% of total shares, while Chongqing Urban Construction Investment (Group) Co., Ltd. holds 282,294,397 shares, representing 16.33%[9] - The top 10 shareholders include state-owned and private entities, with the largest shareholder being a state-owned enterprise[9] Strategic Developments - The company is undergoing a strategic integration that may lead to changes in its controlling shareholder and actual controller, which is still in the planning stage[13] - A 2% equity transfer agreement has been signed, which will change the indirect controlling shareholder to China General Technology (Group) Holding, pending regulatory approvals[14] - The company has received a decision from the National Market Supervision Administration allowing the equity transfer to proceed without further antitrust review[14] Inventory and Receivables - Accounts receivable increased by 8.03% to ¥35,542,943,591.86 compared to the beginning of the year[6] - Inventory grew by 26.70% to ¥10,040,177,140.51, primarily due to increased stock for national procurement policies[6] - Accounts receivable increased to approximately RMB 35.54 billion from RMB 32.90 billion, indicating a growth of about 8.2%[15] - Prepayments rose significantly to approximately RMB 2.57 billion, up from RMB 1.58 billion, reflecting a growth of about 62.4%[15] - Inventory increased to CNY 10.04 billion in Q3 2024 from CNY 7.92 billion in Q3 2023, reflecting a growth of approximately 26.69%[16] Expenses - The company’s financial expenses decreased by 17.39% to ¥813,810,366.43, attributed to a reduction in interest-bearing liabilities[7] - Financial expenses decreased to CNY 813,810,366.43 from CNY 985,081,789.15, a reduction of 17.4%[18] - Research and development expenses increased significantly to CNY 8,576,219.24, up from CNY 3,492,571.78, marking a 145.5% increase year-over-year[18] - The company’s tax expenses for the quarter were CNY 140,237,633.89, down from CNY 171,451,320.31, a decrease of 18.2%[18]